Latest news
Ascletis Begins Phase I Studies of Amylin Agonist ASC36 and Its GLP-1/GIP Co-Formulation for Obesity - biopharminternational.combiopharminternational.com · Mon, 10 Aug 2026 19:50:09 GMTHeart disease deaths rising as obesity, high blood sugar offset decades of progress - Northern News NowNorthern News Now · Mon, 10 Aug 2026 19:35:00 GMTBHMA adds obesity medicine specialist - timesnews.nettimesnews.net · Mon, 10 Aug 2026 19:04:51 GMTEli Lilly's weight-loss pill secures first European nod in Britain - ReutersReuters · Mon, 10 Aug 2026 18:50:16 GMTNew GLP-1 pill delivers up to 12% weight loss in 36 weeks - ScienceDailyScienceDaily · Mon, 10 Aug 2026 14:51:45 GMTIt’s not just willpower: How obesity may change communication in the adolescent brain - musc.edumusc.edu · Mon, 10 Aug 2026 14:13:32 GMTWhy choosing low-fat dairy is not necessarily better for your health - aljazeera.comaljazeera.com · Mon, 10 Aug 2026 13:36:57 GMTNeurocrine begins Phase I trial of NBIP-‘1968 triple agonist for obesity - Clinical Trials ArenaClinical Trials Arena · Mon, 10 Aug 2026 13:34:39 GMT